However, the company announced its fourth-quarter results after the market closed on Thursday. The healthcare stock fell 4% in after-hours trading. Here are the highlights from GoodRx's Q4 update.
By the numbers
GoodRx reported revenue in the fourth quarter of $153.5 million. This reflected a 36% increase from the prior-year period revenue total of $113.3 million. The consensus among Wall Street analysts projected Q4 revenue of $147.8 million.
How did GoodRx's bottom line look in the fourth quarter? The company reported a net loss of $298.3 million, or $0.74 per share, based on generally accepted accounting principles (GAAP). This compared to net income of $15.2 million, or $0.04 per share, in the same period in 2019.
The company's adjusted net income in the fourth quarter totaled $32.2 million, or $0.08 per share. This was an increase from GoodRx's adjusted earnings of $23 million, or $0.06 per share, in the prior-year period. It was also better than the consensus analysts' adjusted earnings estimate of $0.07 per share.
Behind the numbers
GoodRx's strong revenue growth in the fourth quarter was driven primarily by higher prescription transaction volume. The company reported Q4 prescription transaction revenue of $131.3 million, up 26% year over year. Monthly active consumers jumped 32% year over year despite continuing COVID-19 headwinds.
The company's prescription transaction revenue increase could have been even higher. GoodRx noted that it experienced a very weak cold and flu season.
Other revenue soared 153% year over year to $22.2 million. This figure included growth from rebates from drug manufacturers and telehealth services.
With such an impressive top-line performance, why did GoodRx's GAAP bottom line deteriorate? The company recorded a $296.7 million increase in stock-based compensation expense and payroll tax expense. In addition, GoodRx had a $41.7 million non-cash non-recurring charge.
GoodRx anticipates that revenue for the first quarter of 2021 will be between $158 million and $161 million. This reflects close to 20% year-over-year growth at the midpoint of the range, but it was a little lower than anticipated. The company also expects that the full year 2021 revenue will fall between $735 million and $755 million, an increase of around 35%.
Co-CEOs Doug Hirsch and Trevor Bezdek said that the company sees 2021 as a "massive opportunity to bring more value to our consumers at each stage of their healthcare journey." They also added that GoodRx "remain[s] intently focused on continuing to strengthen our brand and broaden our reach, taking our content and insights to the next level, and investing in our platform to launch new products and services."